- Home
- SGMT vs ARTV Comparison
SGMT vs ARTV Comparison
Compare SGMT & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- ARTV
- Stock Information
- Founded
- SGMT 2006
- ARTV 2019
- Country
- SGMT United States
- ARTV United States
- Employees
- SGMT N/A
- ARTV N/A
- Industry
- SGMT
- ARTV
- Sector
- SGMT
- ARTV
- Exchange
- SGMT Nasdaq
- ARTV NYSE
- Market Cap
- SGMT 71.2M
- ARTV 61.9M
- IPO Year
- SGMT 2023
- ARTV 2024
- Fundamental
- Price
- SGMT $3.55
- ARTV $1.93
- Analyst Decision
- SGMT Strong Buy
- ARTV Strong Buy
- Analyst Count
- SGMT 6
- ARTV 7
- Target Price
- SGMT $25.67
- ARTV $19.17
- AVG Volume (30 Days)
- SGMT 392.3K
- ARTV 147.5K
- Earning Date
- SGMT 05-08-2025
- ARTV 05-08-2025
- Dividend Yield
- SGMT N/A
- ARTV N/A
- EPS Growth
- SGMT N/A
- ARTV N/A
- EPS
- SGMT N/A
- ARTV N/A
- Revenue
- SGMT N/A
- ARTV N/A
- Revenue This Year
- SGMT N/A
- ARTV N/A
- Revenue Next Year
- SGMT N/A
- ARTV N/A
- P/E Ratio
- SGMT N/A
- ARTV N/A
- Revenue Growth
- SGMT N/A
- ARTV N/A
- 52 Week Low
- SGMT $1.73
- ARTV $1.78
- 52 Week High
- SGMT $7.38
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- SGMT 57.81
- ARTV N/A
- Support Level
- SGMT $3.18
- ARTV N/A
- Resistance Level
- SGMT $3.85
- ARTV N/A
- Average True Range (ATR)
- SGMT 0.27
- ARTV 0.00
- MACD
- SGMT 0.01
- ARTV 0.00
- Stochastic Oscillator
- SGMT 61.04
- ARTV 0.00
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).